NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

770.00 -1.12 (-0.15%)
At close: May 17 at 4:00 PM EDT
771.62 +1.62 (+0.21%)
After hours: May 17 at 7:58 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
35,932,100.00
34,124,100.00
28,541,400.00
28,318,400.00
24,539,800.00
Cost of Revenue
7,129,000.00
7,082,200.00
6,629,800.00
7,312,800.00
5,483,300.00
Gross Profit
28,803,100.00
27,041,900.00
21,911,600.00
21,005,600.00
19,056,500.00
Operating Expense
16,995,000.00
16,254,600.00
13,258,300.00
13,072,600.00
11,955,100.00
Operating Income
11,808,100.00
10,787,300.00
8,653,300.00
7,933,000.00
7,101,400.00
Net Non Operating Interest Income Expense
-377,500.00
-312,300.00
-268,800.00
-314,400.00
-326,600.00
Other Income Expense
-3,869,600.00
-3,920,400.00
-1,578,100.00
-1,463,100.00
455,100.00
Pretax Income
7,561,000.00
6,554,600.00
6,806,400.00
6,155,500.00
7,229,900.00
Tax Provision
1,422,600.00
1,314,200.00
561,600.00
573,800.00
1,036,200.00
Net Income Common Stockholders
6,138,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Diluted NI Available to Com Stockholders
6,138,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Basic EPS
6.82
5.82
6.57
5.85
6.47
Diluted EPS
6.79
5.80
6.57
5.85
6.47
Basic Average Shares
900,131.00
900,181.00
950,182.00
953,653.00
956,590.00
Diluted Average Shares
903,409.00
903,284.00
950,182.00
953,653.00
956,590.00
Total Expenses
24,124,000.00
23,336,800.00
19,888,100.00
20,385,400.00
17,438,400.00
Net Income from Continuing & Discontinued Operation
6,138,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Normalized Income
9,274,983.57
8,346,672.30
7,678,804.60
6,955,351.50
5,636,135.80
Interest Income
185,200.00
173,600.00
62,800.00
25,400.00
33,000.00
Interest Expense
562,700.00
485,900.00
331,600.00
339,800.00
359,600.00
Net Interest Income
-377,500.00
-312,300.00
-268,800.00
-314,400.00
-326,600.00
EBIT
8,123,700.00
7,040,500.00
7,138,000.00
6,495,300.00
7,589,500.00
EBITDA
9,689,300.00
8,567,800.00
8,660,500.00
8,042,900.00
8,913,400.00
Reconciled Cost of Revenue
7,129,000.00
7,082,200.00
6,629,800.00
7,312,800.00
5,483,300.00
Reconciled Depreciation
1,565,600.00
1,527,300.00
1,522,500.00
1,547,600.00
1,323,900.00
Net Income from Continuing Operation Net Minority Interest
6,138,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Total Unusual Items Excluding Goodwill
-3,863,500.00
-3,887,700.00
-1,563,800.00
-1,514,500.00
650,600.00
Total Unusual Items
-3,863,500.00
-3,887,700.00
-1,563,800.00
-1,514,500.00
650,600.00
Normalized EBITDA
13,552,800.00
12,455,500.00
10,224,300.00
9,557,400.00
8,262,800.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-726,916.43
-781,427.70
-129,795.40
-140,848.50
93,035.80
12/31/2020 - 6/1/1972

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ABBV AbbVie Inc.
166.42
+1.26%
 
AMGN Amgen Inc.
312.47
-0.71%
 
MRK Merck & Co., Inc.
131.19
+0.24%
 
PFE Pfizer Inc.
28.64
-0.97%
 
JNJ Johnson & Johnson
154.64
+0.23%
 
BMY Bristol-Myers Squibb Company
44.03
-0.18%
 
BIIB Biogen Inc.
230.57
+0.23%
 
GILD Gilead Sciences, Inc.
67.72
-0.21%
 
AZN AstraZeneca PLC
76.90
-0.18%
 
NVS Novartis AG
102.57
-0.12%